← Back to Screener
Allarity Therapeutics, Inc. Common Stock (ALLR)
Price$1.72
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)49.23%
Price vs S&P 500 (4W)21.18%
VGM Score71.77
Market Capitalization$26.09M
All Metrics
Book Value / Share (Quarterly)$0.44
P/TBV (Annual)0.44x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.06
Price vs S&P 500 (YTD)40.92%
EPS (TTM)$-0.72
10-Day Avg Trading Volume0.29M
EPS Excl Extra (TTM)$-0.72
EPS (Annual)$-0.78
ROI (Annual)-100.03%
Cash / Share (Quarterly)$1.25
ROA (Last FY)-61.51%
EBITD / Share (TTM)$-0.79
ROE (5Y Avg)-268.07%
Cash Flow / Share (Annual)$-0.92
P/B Ratio3.77x
P/B Ratio (Quarterly)2.49x
Net Income / Employee (Annual)$-1,604,400
Net Interest Coverage (TTM)-12.89x
ROA (TTM)-47.27%
EPS Incl Extra (Annual)$-0.78
Current Ratio (Annual)2.13x
Quick Ratio (Quarterly)1.11x
3-Month Avg Trading Volume0.19M
52-Week Price Return83.86%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.62
P/S Ratio (Annual)81.54x
Asset Turnover (Annual)0.02x
52-Week High$2.35
EPS Excl Extra (Annual)$-0.78
CapEx CAGR (5Y)21.67%
26-Week Price Return65.16%
Quick Ratio (Annual)1.88x
13-Week Price Return64.82%
Total Debt / Equity (Annual)0.14x
Current Ratio (Quarterly)1.23x
Enterprise Value$27.78M
Revenue / Employee (Annual)$45,700
Pretax Margin (Annual)-3509.69%
Cash / Share (Annual)$0.92
3-Month Return Std Dev85.19%
Net Income / Employee (TTM)$-1,607,000
ROE (Last FY)-114.28%
Net Interest Coverage (Annual)-10.09x
EPS Basic Excl Extra (Annual)$-0.78
Total Debt / Equity (Quarterly)3.11x
EPS Incl Extra (TTM)$-0.72
ROI (TTM)-67.57%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$1.62
Price vs S&P 500 (52W)55.65%
Year-to-Date Return51.85%
5-Day Price Return-7.34%
EPS Normalized (Annual)$-0.78
ROA (5Y Avg)-86.83%
Net Profit Margin (Annual)-3509.69%
Month-to-Date Return21.48%
Cash Flow / Share (TTM)$-30.29
EBITD / Share (Annual)$-0.88
Operating Margin (Annual)-3939.06%
LT Debt / Equity (Annual)0.57x
ROI (5Y Avg)-146.34%
LT Debt / Equity (Quarterly)0.57x
EPS Basic Excl Extra (TTM)$-0.72
P/TBV (Quarterly)0.44x
P/B Ratio (Annual)1.76x
Book Value / Share (Annual)$0.61
Price vs S&P 500 (13W)55.08%
Beta0.55x
Revenue / Share (TTM)$0.00
ROE (TTM)-109.94%
52-Week Low$0.77
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.17est. -0.22
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALLRAllarity Therapeutics, Inc. Common Stock | — | — | B | $1.72 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Allarity Therapeutics is a clinical-stage pharmaceutical company developing stenoparib, an oral small-molecule inhibitor for advanced recurrent ovarian cancer. The company uses its proprietary Drug Response Predictor (DRP) technology to identify patients most likely to benefit from treatment, combining precision medicine with oncology. Operating in Denmark and the United States, Allarity is focused on addressing a significant unmet medical need in ovarian cancer treatment.